bluebird bio, Inc. (BLUE)
(Delayed Data from NSDQ)
$28.12 USD
+2.20 (8.49%)
Updated Feb 25, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value C Growth B Momentum D VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
bluebird (BLUE) Q4 Loss Narrower than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) reports a narrower-than-expected loss but misses sales estimates in the fourth quarter of 2020.
BMYNegative Net Change BLUEPositive Net Change CLSDNegative Net Change AVIRPositive Net Change
biotechs
Biotech Stock Roundup: REGN's Drug Approval & Pipeline Updates From AMGN, BLUE
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Amgen (AMGN) and bluebird (BLUE).
REGNNegative Net Change AMGNNegative Net Change CRTXNo Net Change BLUEPositive Net Change ACIUNegative Net Change
biotechs
bluebird (BLUE) Down on Suspension of Sickle Cell Disease Studies
by Zacks Equity Research
bluebird (BLUE) temporarily suspends two studies of LentiGlobin gene therapy in SCD because of reported Suspected Unexpected Serious Adverse Reactions of acute myeloid leukemia.
ACORNegative Net Change BLUEPositive Net Change CLSDNegative Net Change AVIRPositive Net Change
biotechs
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BLUEPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
New Strong Sell Stocks for January 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
HRLPositive Net Change ADPTNegative Net Change BLUEPositive Net Change LOOPNegative Net Change KRUSNegative Net Change
consumer-staples medical restaurants
Harpoon's (HARP) Multiple Myeloma Candidate Gets Orphan Drug Tag
by Zacks Equity Research
Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.
JNJPositive Net Change BMYNegative Net Change BLUEPositive Net Change HARPPositive Net Change
pharmaceuticals
Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY
by Zacks Equity Research
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.
REGNNegative Net Change GILDNegative Net Change BLUEPositive Net Change VIRNegative Net Change CVACNegative Net Change
biotechs
bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity
by Zacks Equity Research
bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.
BMYNegative Net Change HALONegative Net Change BLUEPositive Net Change RCUSNegative Net Change
biotechs
J&J (JNJ) Begins Rolling BLA Filing of Multiple Myeloma Drug
by Zacks Equity Research
J&J (JNJ) initiates the rolling submission of its BLA to the FDA for BCMA CAR-T therapy, ciltacabtagene autoleucel to treat adults with relapsed/refractory multiple myeloma.
IRWDNegative Net Change JNJPositive Net Change BMYNegative Net Change BLUEPositive Net Change
pharmaceuticals
Bluebird (BLUE) Down 3.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BLUEPositive Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.
ADCTNegative Net Change BMYNegative Net Change EBSNegative Net Change BLUEPositive Net Change
biotechs
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 4.23% and -25.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BLUEPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Sorrento (SRNE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on earnings and revenues when its releases third-quarter 2020 results.
BLUEPositive Net Change ASNDPositive Net Change SRNENegative Net Change AXLAPositive Net Change
pharmaceuticals
Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.
BLUEPositive Net Change CPRXNegative Net Change ASNDPositive Net Change AXLAPositive Net Change
pharmaceuticals
Will Bluebird Bio (BLUE) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BLUEPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status
by Zacks Equity Research
GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.
NVSNegative Net Change GLYCNegative Net Change BLUEPositive Net Change GBTNegative Net Change
pharmaceuticals
bluebird's MAA for Elivaldogene Autotemcel Accepted by EMA
by Zacks Equity Research
bluebird's (BLUE) MAA for elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy is accepted by the the European Medicines Agency.
EBSNegative Net Change HZNPNegative Net Change LGNDPositive Net Change BLUEPositive Net Change
biotechs
bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA
by Zacks Equity Research
The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.
BMYNegative Net Change EBSNegative Net Change TECHNegative Net Change BLUEPositive Net Change
biotechs
Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
BMYNegative Net Change SGENNegative Net Change BLUEPositive Net Change ARWRNegative Net Change BPMCNegative Net Change VCNXNegative Net Change
biotechs
Bluebird (BLUE) Down 7.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BLUEPositive Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 81.15% and 95.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BLUEPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
BioNTech (BNTX) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
During BioNTech's (BNTX) upcoming Q2 earnings conference, investors will keep track of the advancement of its COVID-19 vaccine candidate being developed in partnership with Pfizer.
PFEPositive Net Change BLUEPositive Net Change ICPTNegative Net Change BNTXNegative Net Change
biotechs
MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.
BMYNegative Net Change ARCTNegative Net Change BLUEPositive Net Change MEIPNegative Net Change
pharmaceuticals
Why Earnings Season Could Be Great for bluebird bio (BLUE)
by Zacks Equity Research
bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BLUEPositive Net Change
earnings medical
Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results
AMRNNegative Net Change ACADNegative Net Change BLUEPositive Net Change ZOMNegative Net Change
pharmaceuticals